IRIS
NOZZA, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 388
NA - Nord America 273
AS - Asia 246
SA - Sud America 2
Totale 909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 271
SE - Svezia 160
CN - Cina 139
RU - Federazione Russa 117
SG - Singapore 93
IT - Italia 67
FI - Finlandia 24
DE - Germania 8
ID - Indonesia 6
IE - Irlanda 4
IN - India 3
CA - Canada 2
GB - Regno Unito 2
JP - Giappone 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AT - Austria 1
BE - Belgio 1
ES - Italia 1
FR - Francia 1
KZ - Kazakistan 1
NL - Olanda 1
PE - Perù 1
PH - Filippine 1
UA - Ucraina 1
Totale 909
Salva come PNG Salva come JPEG
Città #
Singapore 53
Lawrence 51
Princeton 51
New York 48
Shanghai 46
Moscow 40
Milan 23
Boardman 19
Ashburn 15
Helsinki 15
Guangzhou 13
St Petersburg 9
Gatchina 7
Lappeenranta 7
Busto Arsizio 6
Perm 6
Beijing 5
Shenzhen 5
Yekaterinburg 5
Dublin 4
Jakarta 4
Monsummano Terme 4
Nizhniy Novgorod 4
Xi'an 4
Campodolcino 3
Rome 3
Seattle 3
Voronezh 3
Aversa 2
Catania 2
Dallas 2
Hanover 2
Huskvarna 2
Kuopio 2
Padova 2
Povegliano 2
Pune 2
Quanzhou 2
Stockholm 2
Tokyo 2
Vaprio d'Adda 2
Vittoria 2
Wuxi 2
Almaty 1
Andover 1
Banda Aceh 1
Bolgare 1
Bologna 1
Borås 1
Brussels 1
Cernusco sul Naviglio 1
Chelyabinsk 1
Cuneo 1
Falkenstein 1
Forlì 1
Frankfurt am Main 1
Fuzhou 1
Huzhou 1
Ivanovo 1
Jiaxing 1
Lima 1
Littleton 1
London 1
Los Angeles 1
Madrid 1
Mandaluyong 1
Munich 1
Naaldwijk 1
Nanjing 1
Ottawa 1
Paris 1
Pescara 1
Pisa 1
Puerto Eldorado 1
Rostov-on-Don 1
Sacramento 1
San Francisco 1
Shenyang 1
Taizhou 1
Ternate 1
Tianjin 1
Toronto 1
Verdellino 1
Viterbo 1
Washington 1
Wuyuan 1
Xiamen 1
Totale 530
Salva come PNG Salva come JPEG
Nome #
Viral bloodstream detection in mpox patients: An observational multicentric study 65
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 33
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 27
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 22
Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection–results of Italian network of acute HIV infection (Inaction) retrospective study 22
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 21
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 21
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 20
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 19
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 18
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 18
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 18
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 17
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 17
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 17
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 16
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 16
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 16
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 16
Late positivization of oropharyngeal, plasma, anal, semen, and urine specimens which tested negative at the time of mpox diagnosis 15
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients 15
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. 15
B-cell subset alterations and correlated factors in HIV-1 infection 15
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 15
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 14
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 14
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 14
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 13
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism 13
Durability of a novel salvage therapy in R5 HIV-infected patients: maraviroc, raltegravir, etravirine 13
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 13
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 12
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 12
Rapid improvement of severe Mpox lesions with oral tecovirimat 12
Ageing with HIV: a multidisciplinary review 12
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 12
Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients 12
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 12
Human seminal plasma stimulates the migration of CD11c+ mononuclear phagocytes to the apical side of the colonic epithelium without altering the junctional complexes in an ex vivo human intestinal model 12
Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis 12
Two individuals with potential monkeypox virus reinfection 11
Complexity and Dynamics of HIV-1 Chemokine Receptor Usage in a Multidrug-Resistant Adolescent 11
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy 11
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 11
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells 11
Isolated monkeypox proctitis among men who have sex with men 10
Mpox Virus: Control of In-Hospital Occupational Transmission Experience from a Tertiary Level Hospital in Milan, Italy 10
Persistent ocular mpox infection in an immunocompetent individual 10
Immune recovery and T cell subset analysis during effective treatment with maraviroc 10
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients 10
Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART 10
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 10
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: Maraviroc, raltegravir, etravirine 10
Role of multi-site sampling in the diagnosis of human Monkeypox 9
Mpox in people with past infection or a complete vaccination course: a global case series 9
Immortal time bias: authors' reply 9
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 9
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 9
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 9
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up 9
Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient 9
Influence of gender in predicting CCR5 coreceptor usage 9
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 9
HIV viral load monitoring during monkeypox virus infection among people with HIV 8
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 8
Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients 8
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens 8
RPV plus DRV/cobi as 2DR option in HIV-infected subjects on virologic suppression 8
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience 7
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. 7
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 7
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts 7
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients. 7
Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2 6
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 6
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 6
Rectal Lymphogranuloma venereum among Men who Have Sex with Men: 7 versus 21 Days Doxycycline Effectiveness 3
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 3
Monkeypox Virus Neutralizing Antibodies at Six Months from Mpox Infection: Virologic Factors Associated with Poor Immunologic Response 2
Evaluation of analytical performance of the STANDARDTM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus 2
Tick-borne encephalitis seroprevalence in northern Italy: a cross-sectional study on a randomly selected population 2
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 2
Totale 1.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.209
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.209
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 1 6 0 0 0 0
2021/202238 0 0 0 14 2 2 2 4 0 7 0 7
2022/2023280 114 66 14 2 1 30 12 30 5 2 1 3
2023/2024332 8 10 42 31 38 82 15 31 1 10 20 44
2024/2025331 130 18 41 67 75 0 0 0 0 0 0 0
Totale 1.028